• SIS3 and Smad3 in Early Osteoarthritis

  2026-10-14

  Published rat and cell-model evidence links SIS3-associated Smad3 inhibition with increased miR-140 and reduced ADAMTS-5 expression in early osteoarthritis. The findings support a mechanistic hypothesis involving TGF-β/Smad signaling, but they do not yet establish direct pathway mediation, durable cartilage protection, or therapeutic efficacy. Supplier descriptions of SIS3 and claims in fibrosis or renal disease should be kept separate from the named-material evidence reported in the osteoarthritis study.

• PBS Liposomes: Evidence and Boundaries

  2026-10-14

  PBS Liposomes are described by APExBIO as blank, phosphate-buffered saline–containing liposomes intended as a comparison control in macrophage depletion research. The supplied TRPM3 structural study provides relevant biological context for ion-channel pharmacology but does not validate this product, macrophage depletion controls, or cross-domain experimental claims.

• C8-HSL and Lung Cancer: What the Study Shows

  2026-10-13

  A source-grounded overview of Liu et al. (2026), which examined whether the quorum-sensing molecule C8-HSL affects lung cancer cell behavior. The study reports increased proliferation, migration, and invasion in H460 cells and associates these effects with PI3K/AKT/ERK signaling, but its findings remain preclinical and model-limited.

• NMDA in Retinal Excitotoxicity Research

  2026-10-13

  NMDA (N-Methyl-D-aspartic acid) is used in neuroscience as a receptor-mediated excitotoxicity model. A 2025 mouse study used NMDA-associated retinal injury to examine BMP4–GPX4 signaling, ferroptosis-related changes and retinal stem-cell differentiation, while also illustrating why this model should not be treated as a complete representation of human glaucoma.

• What the 2025 mRNA Protocol Demonstrates

  2026-10-12

  Leighton and colleagues present a small-scale, end-to-end framework for producing and evaluating research-grade mRNA, linking sequence design, DNA-template preparation, in vitro transcription, lipid-nanoparticle formulation and cell-based assessment. Its evidence supports workflow feasibility, but does not establish universal performance, clinical safety or therapeutic efficacy.

• 3-Hydroxybutyrate and Stroke: Evidence Boundaries

  2026-10-12

  A source-grounded overview of a 2024 rat and cell study linking remote ischemic postconditioning with ketone-body-associated ferroptosis changes, while distinguishing reported findings from claims that remain unproven for 3-hydroxybutyrate (BHBA) specifically.

• circStep and Native Protein Dynamics: An Editorial

  2026-10-11

  The supplied record describes circStep, an allosteric fluorogenic aptamer biosensor for visualizing endogenous protein localization and abundance dynamics in living cells. Its conceptual promise is substantial, but the available evidence is insufficient to judge generality, quantitative performance, or drug-screening validity; Biotin-16-UTP is a separate RNA-labeling product and is not documented as part of the cited study.

• RIPostC, Ketone Bodies, and Ferroptosis in Stroke

  2026-10-10

  A 2024 ACS Chemical Neuroscience study identifies ketone-body-associated suppression of ferroptosis as a possible mechanism linking remote ischemic postconditioning with neuroprotection after ischemic stroke. Its rat and HT22-cell findings connect improved energy metabolism with GPX4 preservation, ACSL4 reduction, iron regulation, and mitochondrial protection, while leaving the contribution of individual ketone species unresolved.

• Keap1–Nrf2 Ferroptosis in Alzheimer’s Disease

  2026-10-09

  A 2026 Bioorganic Chemistry study identifies compound 4–95, a Keap1–Nrf2 protein–protein interaction inhibitor, as a preclinical strategy for reducing neuronal ferroptosis and Alzheimer’s disease-like pathology. Across cell and mouse models, the reported effects connect Nrf2 activation with improved antioxidant defenses, reduced amyloid and tau-related abnormalities, and better cognitive performance, while remaining subject to important translational limitations.

• Pazopanib (GW-786034): Research Evidence and Limits

  2026-10-09

  This overview examines Pazopanib (GW-786034) as a multi-targeted receptor tyrosine kinase inhibitor in cancer research, with emphasis on ATRX-deficient high-grade glioma. It separates supplier-described pharmacology from peer-reviewed findings, evaluates the rationale for angiogenesis inhibition and tumor growth suppression, and outlines evidence limitations, including the absence of compound-specific conclusions in the supplied ATRX study.

• Anlotinib Hydrochloride: Evidence and Research Context

  2026-10-08

  An evidence-focused overview of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor, covering anti-angiogenic mechanisms, reported laboratory findings, a rare-tumor case report, evidence strength, and applicability limits.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that selected p38α MAP kinase inhibitors can do more than occupy the kinase active site: they can also increase WIP1-mediated dephosphorylation of the kinase activation loop. Structural and biochemical evidence links this effect to an inhibitor-stabilized activation-loop conformation, suggesting a route toward kinase inhibitors that influence both catalytic activity and signaling-state reset.

• Cefiderocol Activity in Resistant European Nonfermenters

  2026-10-07

  The ARTEMIS study compared cefiderocol with established and emerging β-lactam/β-lactamase inhibitor combinations across 1,451 European Pseudomonas aeruginosa and Acinetobacter spp. isolates. Its principal contribution is the large, geographically distributed in vitro dataset showing high cefiderocol susceptibility among meropenem-resistant and comparator-resistant non-fermenters, while also identifying genetic patterns associated with cefiderocol resistance.

• ICAA Disrupts HBV Replication via HO-1 and ROS

  2026-10-07

  The reference study identifies isochlorogenic acid A (ICAA) as a multitarget inhibitor of hepatitis B virus replication, linking HO-1 induction and reactive oxygen species modulation to effects on viral transcription, cccDNA, capsid formation, and envelopment. Its main contribution is mechanistic integration: rather than treating antiviral activity as a single replication endpoint, the study maps ICAA-associated changes across several stages of the HBV life cycle while defining the limits of cell-based evidence.

• Promethazine HCl in Host-Directed Immunity Research

  2026-10-06

  Promethazine HCl is a phenothiazine-derived histamine H1 antagonist used as a pharmacological research probe. A 2025 Frontiers in Immunology study reported that phenothiazines enhanced macrophage antibacterial activity alongside increased reactive oxygen species, lysosomal activity, and autophagy. However, the strongest in vivo evidence involved perphenazine rather than promethazine, so class-level findings should not be treated as proof of equivalent promethazine activity. This overview separates reported results from interpretation and defines the evidence, research applications, and limitations.

8096 records 1/540 page Next 12345 下5页 Last page